But the rationale is sound: GLP-1 receptors exist on a continuum of activation, and partial activation may produce partial benefits with fewer side effects
The dose is escalated gradually over several months, starting at 2.5 mg and increasing up to a maximum of 15 mg, allowing the body to adjust and minimising the severity of side effects
The main drawback is shipping
49 A recent systematic review and meta-analysis involving obese individuals without diabetes demonstrated that tirzepatide, semaglutide, liraglutide, and exenatide significantly increased the risk of GI adverse events compared with placebo
SGLT2is reduced the risk of major adverse cardiovascular events (MACE) in participants both receiving and not receiving GLP1-RAs, HR 0.81 (95% CI 0.631.03) vs HR 0.90 (95% CI 0.860.94
Peptide Therapy for Fat Loss: Does It Really Work